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Abstract
Mutations in the creatine (Cr) transporter (CrT) gene lead to cerebral creatine
deficiency syndrome-1 (CCDS1), an X-linked metabolic disorder characterized
by cerebral Cr deficiency causing intellectual disability, seizures, movement 
and behavioral disturbances, language and speech impairment ( OMIM
#300352).
CCDS1 is still an untreatable pathology that can be very invalidating for
patients and caregivers. Only two murine models of CCDS1, one of which is an
ubiquitous knockout mouse, are currently available to study the possible
mechanisms underlying the pathologic phenotype of CCDS1 and to develop
therapeutic strategies. Given the importance of validating phenotypes and
efficacy of promising treatments in more than one mouse model we have
generated a new murine model of CCDS1 obtained by ubiquitous deletion of
5-7 exons in the gene. We showed a remarkable Cr depletion in theSlc6a8 
murine brain tissues and cognitive defects, thus resembling the key features of
human CCDS1. These results confirm that CCDS1 can be well modeled in
mice. This CrT  murine model will provide a new tool for increasing the
relevance of preclinical studies to the human disease.
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Introduction
The creatine (Cr) transporter (CrT, alias CRTR, MGC87396, CT1, 
SLC6A8, OMIM 300036) deficiency (CCDS1, OMIM #300352) 
is an X-linked inherited metabolic disorder characterized by cere-
bral Cr deficiency which results in intellectual disability, language 
and speech impairment, seizures and movement and behavioral 
disturbances, and affects about 1% of males with non-syndromic 
mental disability (van de Kamp et al., 2014). CrT loss of func-
tion is mostly caused by missense mutations and small deletions 
which are concentrated in the transmembrane domains 7 and 8 of 
the protein (van de Kamp et al., 2014). In physiological condi-
tions, about half of our normal Cr requirement is satisfied by the 
diet. De novo endogenous synthesis of Cr takes place mainly in 
the kidney, liver and pancreas and involves the enzymes l-arginine: 
glycineamidinotransferase (AGAT) and S-adenosyl-l-methionine:
N-guanidinoacetatemethyltransferase (GAMT) (Wyss & Kaddurah- 
Daouk, 2000). Cr is a polar hydrophilic molecule unable to cross 
the lipidic membranes, which uses a Na+- and Cl−- dependent 
plasma membrane CrT to enter the cells (Nash et al., 1994). CrT is 
widely expressed in the brain tissue with a prominent presence in 
the cortical and subcortical regions involved in motor and sensory 
processing, learning and memory, and regulation of emotion-related 
behavior (Lowe et al., 2014; Mak et al., 2009).
Patients affected by cerebral creatine deficiency syndrome-1 
(CCDS1) share depletion of brain Cr and the clinical phenotype 
with patients carrying the other two defects of Cr metabolism which 
involve mutations of genes encoding the biosynthesizing enzymes 
AGAT and GAMT (Item et al., 2001; Stockler et al., 1994). Replen-
ishment of the brain Cr pool is the only effective therapy for Cr 
deficiency diseases (Battini et al., 2002; Schulze et al., 2001; 
Stockler et al., 1996). Unfortunately, in CCDS1 patients even very 
high doses of Cr, alone or combined with the Cr precursors arginine 
and glycine to stimulate endogenous Cr synthesis, fail to restore the 
Cr content in brain (Chilosi et al., 2008; Valayannopoulos et al., 
2012). There have been attempts to normalize the levels of Cr in 
the brain with Cr-lipophilic analogs, but these compounds have 
proven ineffective when administered to patients (Fons et al., 2010). 
Thus, CCDS1 is still missing an effective treatment.
Preclinical animal models are crucial tools to dissect disease patho-
genic mechanisms and develop new therapeutic strategies. Only 
two murine models of CCDS1 are available so far, and they have 
only been analyzed at the behavioral and neurochemical level. An 
ubiquitous CrT knockout mouse model has been generated by dele-
tion of 2–4 exons in the Slc6a8 gene. Learning and memory defi-
cits, impaired motor activity and Cr depletion in brain and muscles 
have been reported in animals at three-four months of age (Skelton 
et al., 2011). Another murine model is based on the use of the 
CaMKII promoter to drive Cre-recombinase expression, achieving 
a CrT deletion only in postnatal forebrain excitatory neurons. This 
strategy was successful in avoiding the peripheral Cr depletion and 
the motor deficits shown by germline CrT knockout mouse. Behav-
ioral analysis in mice at 12 months of age revealed learning and 
memory impairments that could be ameliorated by supplementation 
of cyclocreatine, a Cr analog (Kurosawa et al., 2012).
For translational studies, the phenotype variations observed in dif-
ferent mouse models, carrying similar mutations and the effects of 
genetic backgrounds highlight the importance of validating phe-
notypes and therapeutic efficacy in multiple models and in differ-
ent laboratories (Katz et al., 2012). Such validation will hopefully 
increase the relevance of preclinical studies to the human disease. 
To increase the number of CCDS1 models, we generated a novel 
murine model of CCDS1 obtained by ubiquitous deletion of 5–7 
exons in the Slc6a8 gene. These mice presented a remarkable Cr 
depletion in the brain tissue and displayed cognitive defects resem-
bling the key features of human CCDS1, and providing a new 
promising CCDS1 animal model.
Materials and methods
Generation of CrT knockout mice
A Cre-conditional allele of Slc6a8 has been produced by introducing 
the loxP sites flanking exon 5–7 of the gene in embryonic stem (ES) 
cells via homologous recombination (vector PRPGS00081_A_A09 
obtained from the NIH Knock-out Mouse Program, KOMP). The 
presence of lox sites has been checked by sequencing (sequencing 
service by MWG, Germany). The plasmid was linearized with NruI 
before electroporation into ES cells (129/Sv x C57BL/6N, clone 
A8, gift of A. Wutz, Wellcome Trust Centre for Stem Cell Research, 
Stem Cell Institute, University of Cambridge). G418-resistant 
clones were identified and screened by long-range PCR (Applied 
Biosystems Gene AMP PCR system 2700). Hybridization with a 
specific probe for the 5′ and 3′ arms was used to confirm the PCR 
results. Two independent positive ES cell clones were injected into 
C57BL/6N host embryos using a piezo-drill assisted 8-cell stage 
injection procedure developed at EMBL, Monterotondo Italy. Four 
out of five offspring (all >95% ES cell derived) provided germline 
transmission. Germline transmission of the allele was confirmed by 
long-range PCR and the neomycin selection cassette was removed 
by crossing with FLP recombinase expressing mice (Farley et al., 
2000). Germline knockout mice were produced by crossing the 
constitutive allele to the HPLRT::Cre recombinase deleter mouse 
(Tang et al., 2002; Figure 1).
Animal housing
Animals were maintained at 22°C under a 12-h light–dark cycle. 
Food (4RF25 GLP Certificate, Mucedola) and water were available 
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ad libitum. The chow was not added with creatine (personal com-
munication of the manufacturer). All experiments were carried out 
in accordance with the European Communities Council Directive 
of 24 November 1986 (86/609/EEC) and were approved by the 
Italian Ministry of Health (authorization number 147/2014-B). All 
necessary efforts were made to minimize both stress and the number 
of animals used. As CrT deficiency is an X-linked pathology and 
only males are consistently affected, we focused our study on male 
animals. Young adult males (postnatal day P40 at the beginning of 
testing) of each genotype (CrT–/y mutants and CrT+/y wild-type lit-
termates) were used in behavioral experiments, while a separate 
group of animals (P30) was assigned to Cr level assay.
Detection of Slc6a8 mutation by PCR
Genomic DNA was isolated from mouse tail using a kit, and the 
protocol suggested by the manufacturer (DNeasy Blood & Tissue 
Kit, Qiagen, USA). DNA was amplified for mutant and wild-type 
(WT) allele using a standard PCR protocol with the following 
primers: F:AGGTTTCCTCAGGTTATAGAGA; R:CCCTAGGT-
GTATCTAACATCT; R1: TCGTGGTATCGTTATGCGCC. For 
PCR amplification we used 300 ng of DNA in a 25 μL reaction 
volume containing 0.2 mM of each dNTP, 2 μM of F primer, 1 μM 
of R, 1 μM of R1 primer and 0.5 U/μL Red Taq DNA polymerase 
(Sigma-Aldrich, Italy). The PCR conditions were as follows: 94°C 
for 4 min followed by 37 cycles at 94°C for 30 s, 58°C for 30 s, 
72°C for 40 s and a final extension at 72°C for 7 min. Amplicons 
were separated using 2% agarose gel and visualized under UV 
light after staining with Green Gel Plus (Fisher Molecular Biology, 
Rome, Italy). Amplicon sizes were: WT allele = 462 bp; mutant 
allele = 371 bp.
Biochemical analysis
For Cr and GAA assay, mouse tissues, immediately frozen on dry 
ice and stored at -80°C until the analysis, were homogenized in 
0.7 ml PBS buffer (Sigma-Aldrich, Italy) at 4°C using a ultrasonic 
disruptor (Microson Heat System, NY, USA) for brain or a glass 
manual homogenizer (VWR, Italy) for kidney, heart and muscle. 
After centrifugation (600 × g for 10 min at 4°C) an aliquot of the 
homogenate (50 μl) was assayed for protein content (Lowry et al., 
1951), and the supernatant used for Cr assay as previously described 
(Alessandri et al., 2005). Briefly, 50 μl of saturated sodium hydro-
gen carbonate and 50 μl of a mixture containing 2- phenylbutyric 
acid (I.S.) in toluene (6.09 mmol/l; Sigma-Aldrich, Italy) were 
added to 200 μl of homogenate or to 100 μl of serum and urine, 
respectively. After adding 1 ml of toluene and 50 μl of hexafluoro-2,4-
pentanedione (Sigma-Aldrich, Italy) to form bis-trifluoromethyl-
pyrimidine derivatives, the mixture was stirred overnight at 80°C. 
The organic layer was centrifuged, dried under nitrogen and 2 μl 
Figure 1. Sketch of the strategy for generation of a null Slc6a8 mouse. A targeting vector was obtained from KOMP to generate mice 
carrying a floxed allele. Crossing these mice with a Flp deleter mouse line produced a conditional KO mouse line (cKO allele). Crossing this 
line with a line expressing Cre-recombinase in the germline produced the Slc6a8 null mouse used in this study (KO allele). 1F, 1R, 2F, 2R, 3F, 
3F’, 3R, 4F, 4R report the sites targeted by the PCR primers to assess allele presence.
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of the residue derivatized at room temperature with 100 μl of 
BSTFA+TMCS (Sigma-Aldrich, Italy) injected into the Gas Chro-
matography/Mass Spectrometry (GC/MS) instrument. GC analyses 
were performed using an Agilent 6890N GC equipped with an 
HP5MS capillary column (0.25 mm × 30 m, film thickness 0.25 ìm) 
and an Agilent mass spectrometer 5973N (Agilent Technologies, 
Italy). The mass spectrometer was set in EI- single ion monitoring 
mode (SIM). The ions with m/z of 192 for I.S., 258 for Cr and 225 
for guanidinoacetic acid (GAA) were used for calculation of the 
metabolites, using standard curves ranging 5–90 μmol/L and 
0.30–6 μmol/L for Cr and GAA, respectively. Data were processed 
by the G1701DA MSD ChemStation software. All the aqueous solu-
tions were prepared using ultrapure water produced by a Millipore 
system. Creatinine in urine was measured using an enzymatic 
colorimetric assay (Sentinel Diagnostics, Italy) and the UV spectro-
photometer Cary50 (Agilent Technologies, Italy) set at 546 nm.
Behavioral testing
The testing order consisted of: open field (1 day duration), object 
recognition test (ORT) at 24h (3 days), Y maze (1 day), Morris 
water maze (MWM) with hidden platform (7 days), and locomotor 
activity (1 day). The mice were tested on one task at a time with the 
next behavioral test starting at least 2 days after the completion of 
the previous one. In order to reduce the circadian effects, all behav-
ioral tests were performed during the same time interval each day 
(1400–1800h; light phase). All behavioral tests were conducted in 
blind with respect to the genotype of animals. Mice were weighed 
at the end of experiments (P60).
Open field and object recognition test (ORT)
We followed the protocol reported in Lonetti et al., 2010. Briefly, 
the apparatus consisted of a square arena (60 × 60 × 30 cm) con-
structed in poly(vinyl chloride) with black walls and a white floor. 
The mice received two sessions of 10-min duration in the empty 
arena on two consecutive days to habituate them to the apparatus 
and test room. Animal position was continuously recorded by a 
video tracking system (Noldus Ethovision XT). In the recording 
software an area corresponding to the center of the arena (a central 
square 30 × 30 cm), and a peripheral region (corresponding to the 
remaining portion of the arena) were defined. The total movement 
of the animal and the time spent in the center or in the periphery 
area were automatically computed. The mice activity during the 
first day of habituation was analyzed for evaluating the behavior in 
the open field arena. The ORT consisted of two phases: sample and 
testing phase. During the sample phase, two identical objects were 
placed in diagonally opposite corners of the arena, approximately 
6 cm from the walls, and mice were allowed 10 min to explore the 
objects, then they were returned to their cage. The objects to be 
discriminated were made of plastic, metal, or glass material and 
were too heavy to be displaced by the mice. Arena and objects were 
cleaned with 10% ethanol between trials to stop the build-up of 
olfactory cues. The testing phase was performed 24h after the sam-
ple phase. One of the two familiar objects was replaced with a new 
one, while the other object was replaced by an identical copy. The 
objects were placed in the same locations as the previous ones. The 
mice were allowed to explore objects for 5 min. To avoid possible 
preferences for one of two objects, the choice of the new and old 
object and the position of the new one were randomized among 
animals. The amount of time spent exploring each object (nose 
sniffing and head orientation within <1.0 cm) was recorded and 
evaluated by the experimenter blind to the mouse genotype. Mice 
exploring the two objects for less than 10 s during the sample phase 
were excluded from testing. A discrimination index was computed 
as DI = (T
new
 - T
old)/(Tnew + Told), where Tnew is the time spent explor-
ing the new object, and T
old is the time spent exploring the old one.
Y maze
Spontaneous alternation was measured using the Y-maze, as 
described in Begenisic et al., 2014. We used a Y-shaped maze with 
three symmetrical grey solid plastic arms at a 120-degree angle 
(26 cm length, 10 cm width, and 15 cm height). Mice were placed 
in the center of the maze and allowed to freely explore the maze for 
8 minutes. The apparatus was cleaned with 10% ethanol between 
trials to avoid the build-up of odor traces. All sessions were video-
recorded for offline blind analysis. The arm entry was defined as all 
four limbs within the arm. A triad was defined as a set of three arm 
entries, when each entry was to a different arm of the maze. The 
number of arm entries and the number of triads were recorded in 
order to calculate the alternation percentage (generated by dividing 
the number of triads by the number of possible alternations and then 
multiplying by 100).
Morris water maze
Mice were trained for four trials per day and for a total of 7 days 
in a circular water tank, made from grey polypropylene (diameter, 
120 cm; height, 40 cm), filled to a depth of 25 cm with water (23°C) 
rendered opaque by the addition of a small amount of a non-toxic 
white paint. Four positions around the edge of the tank were arbi-
trarily designated North (N), South (S), East (E), and West (W), 
which provided four alternative start positions and also defined 
the division of the tank into four quadrants, i.e., NE, SE, SW, and 
NW. A square clear Perspex escape platform (11 × 11 cm) was sub-
merged 0.5 cm below the water surface and placed at the midpoint 
of one of the four quadrants. The hidden platform remained in the 
same quadrant during training, while the start positions (N, S, E, or 
W) were randomized across trials. Mice were allowed up to 60 s 
to locate the escape platform, and their swimming paths were 
automatically recorded by the Noldus Ethovision system. On the 
last trial of the last training day, mice received a probe trial, dur-
ing which the escape platform was removed from the tank and the 
swimming paths were recorded over 60 s while mice searched for 
the missing platform. The swimming paths were recorded and ana-
lyzed with the Noldus Ethovision system.
Measurement of spontaneous locomotor activity
OptoM3 multi-channel activity monitors (Columbus Instruments, 
OH, USA) were used to quantify spontaneous horizontal activity of 
animals. Monitors were placed in the colony area and testing was 
conducted in the same conditions of animal facility housing. All 
measurements were performed from 6:00 P.M. to 6:00 A.M. (dark 
phase) and to 6:00 A.M. to 6:00 P.M. (light phase), using animals 
maintained on a 12 hr light/dark cycle from 6:00 A.M. to 6:00 P.M. 
Individual mice were placed in 33 × 15 × 13-cm (length × width × 
height) clear plastic cages for 24h and total distance travelled was 
calculated from infrared beam breaks by determining activity at 
1-min intervals. Horizontal activity was measured by the sequential 
breaking of infrared beams, 2.54 cm on center, in the horizontal 
plane of the x axis.
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Statistical analysis
All statistical analyses were performed using SigmaStat Software. 
Differences between two groups were assessed with a two-tailed 
t test. The significance of factorial effects and differences among 
more than two groups were evaluated with ANOVA/RM ANOVA fol-
lowed by Holm-Sidak test. Rank transformation was exploited for 
data not normally distributed. The level of significance was p < 0.05.
Results
CrT deletion leads to significant Cr reduction in brain and 
other tissues
In order to determine the effectiveness of our approach for targeting 
CrT gene, the Cr levels were measured by GC/MS in various tis-
sues. We observed a significant reduction of Cr in the brain (both 
cerebral cortex and hippocampus; Two Way ANOVA on rank trans-
formed data, post hoc Holm-Sidak method, p < 0.001), muscle 
(p < 0.001), heart (p < 0.001), kidney (p < 0.05) and serum (p < 0.001) 
of CrT−/y mice with respect to wild-type (WT) littermates (n = 4/tissue 
for each group; Table 1). In contrast, an increase of Cr levels (n = 5 
for CrT−/y mice, n = 4 for WT mice; Two Way ANOVA on rank trans-
formed data, post hoc Holm-Sidak method, p < 0.05) and creatine/
creatinine ratio was present in the urine of mutant (16.95 ± 1.46) 
with respect to WT animals (1.20 ± 0.17; t test, p < 0.001). To ensure 
that kidney Cr reduction was not due to impaired Cr biosynthesis, 
we measured kidney production of guanidinoacetic acid (GAA). 
No difference was observed between CrT–/y (9.76 ± 0.71 nmol/mg 
of protein) and CrT+/y mice (10.70 ± 0.63 nmol/mg of protein; t test, 
p = 0.359). Intriguingly, a moderate change in GAA levels was 
observed in some tissues (Table 2) suggesting that Cr biosynthesis 
is affected by the dramatic Cr decrease caused by CrT deletion.
Reduced body weight growth in CrT–/y mice at two months 
of age
The general appearance of CrT–/y mice was normal and no particu-
lar problems of breeding were observed. To evaluate the effects of 
CrT deletion on body weight, the mice with targeted disruption of 
CrT gene were weighed at P60, and compared with WT littermates. 
CrT−/y animals (n = 9) showed a significantly reduced body weight 
compared to CrT+/y animals (n = 9; t test, p < 0.01; Figure 2).
Normal behavior of CrT–/y mice in the open field arena
We first analyzed the general motor activity and anxiety-related 
behavior of CrT−/y (n = 9) and CrT+/y mice (n = 9) in the open field 
arena. Even though both groups of animals tended to avoid the center 
of the arena, remaining in the peripheral region for a significantly 
longer duration (Two Way ANOVA, post hoc Holm-Sidak method), 
the time spent by CrT−/y mutant mice in both the central and periph-
eral portion of the apparatus was not different from that recorded 
for WT animals (Two Way ANOVA, post hoc Holm-Sidak method, 
p = 0.725 and p = 0.922 respectively; Figure 3a, b, e). No differ-
ence between CrT−/y and CrT+/y animals was present even in motion 
speed and total distance moved (t test, p = 0.807 and p = 0.736 
respectively; Figure 3c, d).
CrT–/y mice display declarative memory deficits in the 
object recognition test
We assessed declarative memory abilities in the object recogni-
tion test (ORT) evaluating animal ability to discriminate a new 
versus a familiar object. During the sample phase (Figure 4a), all 
Table 2. GAA levels in CrT–/y mutant and WT mice. GAA levels 
(mean ± SEM) in CrT–/y and CrT+/y animals (n = 4 per tissue for both 
groups, except n = 5 for urine measurement in CrT−/y mice). An 
increase of GAA levels was present in the brain, muscle and heart 
of mutant animals, while no difference was detected in kidney, 
serum and urine (Two Way ANOVA on rank transformed data, post 
hoc Holm-Sidak method). * p < 0.05; ** p < 0.01; *** p < 0.001.
Tissue (nmol/mg 
protein) CrT-/y CrT+/y
Cerebral cortex 0.114 ± 0.016*** 0.06 ± 0.003
Hippocampus 0.091 ± 0.007*** 0
Muscle 0.282 ± 0.068** 0.106 ± 0.006 
Heart 0.060 ± 0.004*** 0.094 ± 0.010
Kidney 9.758 ± 0.712NS 10.700 ± 0.627
Serum (μmol/l) 2.523 ± 0.105NS 1.738 ± 0.119
Urine (μmol/l) 1114.298 ± 82.551NS 841.043 ± 124.984
Table 1. Depletion of Cr levels in CrT–/y mutant mice. Cr levels 
(mean ± SEM) in CrT–/y and CrT+/y animals (n = 4 per tissue for both 
groups, except n = 5 for urine measurement in CrT−/y mice). Cr 
levels have been measured by GC/MS. A reduction of Cr content 
was evident in the brain, muscle, heart, kidney and serum of 
mutant animals, while an increase of Cr levels was reported in urine 
(Two Way ANOVA on rank transformed data, post hoc Holm-Sidak 
method). * p < 0.05; *** p < 0.001.
Tissue (nmol/mg 
protein) CrT-/y CrT+/y
Cerebral cortex 13.61±1.06*** 76.36 ± 3.16
Hippocampus 14.14 ± 1.52*** 83.69 ± 4.37
Muscle 111.57 ± 21.27*** 310.20 ± 31.59
Heart 1.19 ± 0.27*** 89.92 ± 5.15
Kidney 1.59 ± 0.13* 9.60 ± 0.65
Serum (μmol/l) 44.53 ± 3.88*** 235.02 ± 22.48
Urine (μmol/l) 8680.42 ± 661.58* 3443.69 ± 239.97
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Figure 2. Body weight is lower in CrT–/y animals at two months 
of age. At P60 the weight of CrT–/y mice was significantly reduced 
compared to CrT+/y animals (CrT–/y: 18.75 ± 0.78 g, CrT+/y: 22.77 ± 
0.90 g; t test, p < 0.01). *, statistical significance. Error bars, s.e.m.
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Figure 4. CrT deletion leads to cognitive deficits in object recognition memory. (a) On the left, a schematic representation of the sample 
condition in object recognition task. Histograms depict the performance of CrT–/y and CrT+y during the sample phase: no difference in the 
total exploration time of objects was detected between the experimental groups (CrT–/y: n = 8, exploration time = 56.91 ± 5.40 s; CrT+/y: 
n = 6, exploration time = 67.20 ± 10.23 s; t test, p = 0.358). (b) On the left, a schematic diagram of the test condition. Histograms display 
object discrimination indexes of CrT–/y and CrT+y during the testing phase: a significantly lower discrimination index was found in CrT–/y mice 
(0.261 ± 0.053) compared to CrT+y animals (0.448 ± 0.059; t test, p < 0.05). *, statistical significance. Error bars, s.e.m.
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Figure 3. Normal behavior of CrT mutant mice in the open field arena. (a, b) CrT–/y (n = 9) and CrT+/y mice (n = 9) spent a comparable 
amount of time in the center (CrT–/y: 75.16 ± 10.82 s, CrT+/y: 67.60 ± 18.11 s; a) and in the peripheral region (CrT–/y: 524.41 ± 10.87 s, CrT+/y: 
526.52 ± 18.45 s; b) of the open field arena. A Two-Way ANOVA analysis shows no significant effect of genotype for both comparisons 
(p = 0.725 and p = 0.922, respectively). (c) Walking speed of animals during the exploration of open field arena. We found no significant 
difference (CrT–/y: 7.85 ± 0.43 cm/s, CrT+/y: 7.65 ± 0.71 cm/s; t test, p = 0.807). (d) The total distance moved in the open field arena did not 
differ between CrT mutants (4706.34 ± 258.75 cm) and WT animals (4535.28 ± 427.11 cm; t test, p = 0.736). (e) Representative examples of 
movement path during the open field session for a CrT–/y (left) and a CrT+/y mouse (right). Error bars, s.e.m.
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Figure 5. Impairment of Y-maze spontaneous alternation rate in CrT–/y mice. (a) Schematic diagram of the Y maze apparatus. (b) 
Histograms depict the mean number of entries in the single arms of the maze (A, B, C) and the total number of arm entries for the different 
experimental groups: animals of both groups equally explored all the three arms of the maze and general exploratory behavior of CrT–/y 
animals (n = 9; A: 15.22 ± 1.12, B: 14.22 ± 1.08, C: 12.22 ± 1.05, TOT: 41.67 ± 2.41) was totally comparable to that exhibited by WT littermates 
(n = 9; A: 14.00 ± 1.26, B: 14.11 ± 1.29, C: 15.22 ± 1.27, TOT: 43.33 ± 3.58; Two-Way ANOVA, post hoc Holm-Sidak method, p = 0.640, 
p = 0.966, p = 0.252, p = 0.523 respectively). (c) Alternation rate in the Y maze was significantly lower in CrT–/y mice (49.24 ± 3.20%) 
compared to that recorded for CrT+/y littermates (58.91 ± 2.99%; t test, p < 0.05). *, statistical significance. Error bars, s.e.m.
experimental groups equally explored the objects, with total explo-
ration time of mutant mice (n = 8) very close to that recorded for 
the control group (n = 6; t test, p = 0.358). After a delay of 24h, the 
testing phase revealed that while CrT+/y mice displayed a clear pref-
erence toward the novel object spending a significantly longer time 
exploring it, an impaired performance was found in CrT–/y animals, 
which exhibited a significantly lower discrimination index than 
control animals (t test, p < 0.05, Figure 4b).
Impaired spatial working memory in CrT–/y mice
To evaluate whether CrT deletion may affect spatial working mem-
ory, we used the analysis of spontaneous alternation in the Y maze 
(Figure 5a). Animals of both groups equally explored all the three 
arms of the maze. Indeed, no effect of genotype was detected for 
either the number of entries in the single arms of the maze (desig-
nated A, B, C) or the total number of arm entries, indicating that the 
exploratory disposition of mutant animals (n = 9) was not altered 
compared to WT littermates (n = 9; Two-Way ANOVA, post hoc 
Holm-Sidak method, p = 0.640, p = 0.966, p = 0.252, p = 0.523 
respectively, Figure 5b). In contrast, CrT−/y mice showed a signifi-
cantly smaller rate of spontaneous alternation with respect to WT 
controls (t test, p < 0.05, Figure 5c).
CrT deletion impairs spatial learning and memory in mutant 
mice
We further assessed spatial memory abilities in the Morris water 
maze (MWM) task, a cognitive paradigm which allows testing both 
spatial learning and memory. Since a main effect of genotype was 
found on mean swimming speed recorded all along the training 
phase (t test, p < 0.05; Figure 6a), we analyzed path length, which 
is a quantity independent of swimming velocity. We found that the 
mean distance covered to locate the submerged platform on the 
last three days of training was longer in CrT–/y mice (n = 9) com-
pared to CrT+/y littermates (n = 5; t test, p < 0.05; Figure 6b, c). To 
measure the strength of spatial learning and to discriminate between 
spatial and non-spatial memory strategies we performed a probe trial 
in which the hidden platform was removed and the amount of time 
spent in the former region of the platform was measured. The probe 
test confirmed the spatial memory impairment of CrT–/y mice: CrT+/y 
animals spent significantly longer time in the quadrant where the 
platform was located during the previous learning days (NE*; Two-
Way RM ANOVA, post hoc Holm-Sidak method, p < 0.05 for all 
comparisons); in contrast, CrT–/y mice showed no preference for the 
target quadrant, indicating that they did not remember the location of 
the hidden platform (Two-Way RM ANOVA, post hoc Holm-Sidak 
method; Figure 6d). A statistically significant effect of genotype was 
detected in the time spent exploring the target quadrant (Two-Way 
RM ANOVA, post hoc Holm-Sidak method, p < 0.05; Figure 6d).
Cr depletion reduces spontaneous locomotor activity in 
CrT−/y mice
To investigate the presence of movement impairments in CrT−/y mice 
in a non-aversive environment, we investigated home-cage-locomotor 
activity. We found that CrT–/y mice (n = 9) are significantly less 
active than the CrT+/y group (n = 8, Two-Way ANOVA, post hoc 
Holm-Sidak method, p < 0.001). More specifically, CrT−/y mice 
showed decreased horizontal activity during the night period (Two-
Way ANOVA, post hoc Holm-Sidak method, p < 0.001), while no 
effect of genotype was observed for exploration during daytime 
(p = 0.535; Figure 7a, b).
Dataset 1. Complete data for neurochemical and behavioral 
assessment in a mouse model of creatine transporter deficiency
http://dx.doi.org/10.5256/f1000research.5369.d42180
Detailed descriptions of each dataset can be found in the text file 
provided.
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Figure 6. CrT deletion impairs spatial learning and memory in mutant mice. (a) Mean swimming speed measured all along the training 
phase for CrT–/y and CrT+/y animals: mutant mice (14.00 ± 0.53 cm/s) resulted to be slower swimmers with respect to control littermates 
(16.44 ± 0.60 cm/s; t test, p < 0.05). (b, c) Learning curves for CrT–/y (n = 9; blue) and CrT+/y mice (n = 5; grey) during the training phase. The 
histogram shows the mean swimming path covered to locate the submerged platform on the last three day of training for the two groups. A 
t-test analysis showed a statistical difference between CrT–/y (285.24 ± 37.53 cm) and CrT+/y animals (171.58 ± 23.80 cm; p < 0.05). (d) Probe 
trial. A Two-Way RM ANOVA followed by Holm-Sidak multiple comparison revealed that while CrT+/y spent significantly more time in the NE 
quadrant than in the other ones, CrT–/y did not show any preference for the target quadrant. In addition, the percentage of time spent in the 
target quadrant was shorter in CrT–/y mice (30.31 ± 5.33%) than in the other group (45.73 ± 7.35%). (e) Representative examples of swimming 
path during the probe session for a CrT–/y (left) and a CrT+/y mouse (right). *, statistical significance. Error bars, s.e.m.
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Figure 7. Locomotor activity in CrT–/y mutant mice and the wild-type parental strain. (a) Total horizontal distance travelled throughout 24h 
(left), and over the dark (middle) or light phase (right). CrT–/y mice had a significant decrease in motor activity in comparison to control animals 
during the whole period of testing (CrT–/y: 43,594.22 ± 2,639.39 beam crossings, CrT+/y: 65,587.63 ± 5,831.19 beam crossings) and the night 
phase (CrT–/y: 29,109.67 ± 1,695.35 beam crossings, CrT+/y: 48,094.13 ± 4,843.56 beam crossings; Two-Way ANOVA, post hoc Holm-Sidak 
method, p < 0.001 for both comparisons), while the motor behavior of the two groups was similar in the day-time (CrT–/y: 14,484.56 ± 1,458.08 
beam crossings, CrT+/y: 17,493.50 ± 2,957.57 beam crossings; p = 0.535). (b) Time course of horizontal activity of CrT–/y (blue) and CrT+/y 
(grey) animals during 24h. Data are plotted as total number of beam crossings ± SEM in each time block of 60 min. Dark and light phases 
are indicated. *, statistical significance. Error bars, s.e.m.
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Discussion
We have generated a new murine model of human CrT deficiency 
carrying a loss of function deletion of 5–7 exons in the murine 
orthologous of Slc68a gene. Given that most disease-underlying 
mutations in human CCDS1 lead to loss of CrT function (van de 
Kamp et al., 2014), our model has a good degree of construct valid-
ity. Beyond the genetic deletion, neurochemical abnormalities found 
in CrT−/y mice, reproducing the reduced levels of Cr that character-
ize the brain of CCDS1 patients (van de Kamp et al., 2012), are 
also helpful to confirm the successful disruption of CrT gene and 
the construct robustness of this model. Importantly, Cr deficiency 
is apparent in both the cerebral cortex and hippocampus, i.e., two 
brain regions crucially involved in the patient cognitive defects. 
These results seem to support the hypothesis that, despite AGAT 
and GAMT expression (Carducci et al., 2012; Schmidt et al., 2004; 
Tachikawa et al., 2004), in CrT deficiency conditions endogenous 
synthesis does not compensate for the loss of Cr uptake in the mouse 
(Skelton et al., 2011) as well as in the human brain (Cecil et al., 
2001). In contrast to the preservation of Cr levels in skeletal muscle 
of CCDS1 patients (deGrauw et al., 2003), we observed that mutant 
mice exhibit Cr reductions in muscle and other peripheral tissues 
and body fluids. This observation, which is in agreement with data 
from a different CrT knockout mouse (Russell et al., 2014; Skelton 
et al., 2011), further confirmed that the recombination resulted in a 
ubiquitous disruption of the CrT gene. In particular, the reduction 
of serum Cr level may be explained by defective gut absorption 
from the diet (Garcia-Miranda et al., 2009; Skelton et al., 2011). 
The only body fluid in which Cr levels resulted to be increased is 
urine; it is likely that the lack of a functional transporter impairs 
the creatine salvage normally operated by the kidney (van de Kamp 
et al., 2014). Consistently, we found an elevated creatine/creatinine 
(Cr/Crn) ratio in the urine of mutant mice, probably due to a com-
bination of reduced renal reabsorption of creatine and decreased 
creatinine excretion.
Our behavioral investigation highlighted that CrT−/y mice carrying 
a different deletion than previously reported (Skelton et al., 2011) 
exhibit a broad spectrum of phenotypes establishing the validity 
of this model and corroborating its utility in translational studies. 
Mutant mice, indeed, show cognitive impairments in a battery of learn-
ing and memory tests aimed at assessing both explicit and implicit 
memories such as object-recognition task, Y maze and Morris water 
maze. The memory deficiency assessed across a variety of behavioral 
tasks indicates that CrT−/y animals have a general cognitive impair-
ment, which is a key clinical feature in CCDS1 patients.
While the motor development is only mildly delayed in CCDS1 
patients (van de Kamp et al., 2013) and myopathic symptoms have 
been rarely described (Anselm et al., 2006; van de Kamp et al., 
2013), mostly as late onset deficits (deGrauw et al., 2002; Hahn 
et al., 2002; Kleefstra et al., 2005), we found that reduced mus-
cle levels of Cr measured in mutant animals were accompanied 
by alterations of motor behavior. CrT−/y mice, indeed, showed sig-
nificantly decreased home-cage-locomotor activity (particularly 
evident during the night period) and they were slower swimmers 
than CrT+/y mice. In contrast, we found that vulnerability to stress 
and anxiety responses are not sensitive to CrT deletion. The lack 
of a genotype effect for the motor behavior in the open field test 
may be due to the aversive nature of the arena, which may affect 
the explorative aptitude of both wild-type and mutant mice, thus 
masking the difference in motor activity between the two groups. 
It is worth noting that our data allow to exclude the possibility that 
an impaired motor activity can interfere with the animals’ cognitive 
performance. Indeed, in the ORT sample phase and the Y maze test 
the total exploration of objects and/or arena was equal for mutant 
and control mice, while for the Morris water maze we analyzed 
the path length covered to locate the submerged platform avoiding 
the confounding effects of the reduced swimming speed of mutant 
mice. Future studies using conditional mouse models with a disrup-
tion of CrT allele only in the brain tissue will be useful to dissect 
the role of peripheral Cr in the development of cognitive deficits. It 
has been reported that a CrT deletion exclusively restricted to fore-
brain excitatory neurons during late postnatal development induces 
selective learning and memory deficits without affecting motor 
behavior (Kurosawa et al., 2012).
Because of the importance of Cr in normal retinal function and 
development (Acosta et al., 2005), it has been suggested that an 
alteration of visual capabilities might play a role in the cognitive 
deficits displayed by CrT−/y animals. We reported that during the 
ORT sample phase all experimental groups equally explored and 
observed the objects, with the total exploration time of mutant mice 
very close to that recorded for the control group, suggesting that no 
major impairment is present in the visual system of CrT–/y animals. 
In addition, to avoid possible confounding effects due to reduced 
visual acuity, the tank used in the Morris water maze task was sur-
rounded by a set of extra-maze cues in a visual discrimination range 
detectable even by partially-sighted animals.
In conclusion, this CrT−/y murine model will provide a new tool 
for improving preclinical evaluation of potential CCDS1 interven-
tion treatments. The results confirm previous data suggesting that 
CCDS1 can be well modeled in mice (Kurosawa et al., 2012; 
Skelton et al., 2011). Null mice display an impairment of motor 
behavior rarely present in human patients; however, the use of 
conditional mice will avoid this problem. Since CCDS1 is still an 
untreatable pathology, there is a compelling need for developing 
effective therapeutic strategies. The availability of murine models 
that reliably reproduce the human condition will fuel and support 
the research in this field. To assess the reproducibility and the pre-
dictive validity of promising treatments for CCDS1 as well as for 
other disorders, the validation of findings in more than one animal 
model is strongly desirable prior to launching later-stage transla-
tional or clinical projects (Katz et al., 2012). Since another invali-
dating hallmark of CCDS1 is the frequent occurrence of seizures, 
additional studies in CrT−/y mice analyzing the behavioral response 
to kainic-acid injection will be required to provide useful informa-
tion about seizure susceptibility in this model.
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Data availability
F1000Research: Dataset 1. Complete data for neurochemical and 
behavioral assessment in a mouse model of creatine transporter 
deficiency., 10.5256/f1000research.5369.d42180 (Baroncelli 
et al., 2015).
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Reader Comment 16 Dec 2014
, Skelton Lab
Dr. Schulze,
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Dr. Schulze,
I would like to respectfully clarify an error in your review.  Our ubiquitous CrT mice did indeed show
deficits in object recognition memory, as shown in figure 6 of our .  In fact, thePLOS One paper
object recognition deficit was similar to the deficit presented in this paper.  
Best Regards,
Matthew R. Skelton, Ph.D.
Cincinnati Children's Research Foundation
matthew.skelton@cchmc.org 
 We developed the first CrT KO mice.Competing Interests:
Author Response 15 Jan 2015
, CNR Institute of Neuroscience, Italy, ItalyLaura Baroncelli
As already clarified by Dr. Skelton, our behavioral findings are not at odds with those reported in
his PLOS ONE paper: indeed, their knockout mice show a deficit in object recognition memory very
similar to that measured in our model. The difference in the extent of creatine deficiency is
explained by the different methods employed to measure this metabolite: in our study creatine was
analyzed using gas chromatography/mass spectrometry, a widely accepted specific and sensitive
technique, whereas  used a less sensitive colorimetric method.Skelton  (2011)et al.
 
As regards the mouse chow, the manufacturer told us that the pellet purchased for our animal
facility is not added with creatine. We made this point clearer, adding a sentence in the Materials
and methods section (Animal housing subsection).
 
We followed your suggestion and measured creatine concentration also in body fluids, and more
specifically in serum and urine. We observed a significant reduction of Cr in the serum of CrT
mice with respect to wild-type (WT) littermates (Two Way ANOVA on rank transformed data, post
hoc Holm-Sidak method, p < 0.001). In contrast, an increase of Cr levels (Two Way ANOVA on
rank transformed data,  Holm-Sidak method, p < 0.05) and creatine/ creatinine ratio waspost hoc
present in the urine of mutant with respect to WT animals (t test, p < 0.001). We added these data
in the Result section and in Table 1. We also modified the discussion adding the following
sentences: “In contrast to the preservation of Cr levels in skeletal muscle of CCDS1 patients (
), we observed that mutant mice exhibit Cr reductions in muscle and otherdeGrauw et al., 2003
peripheral tissues and body fluids. This observation, which is in agreement with data from a
different CrT knockout mouse ( ; Skelton ., 2011), further confirmed that theRussell , 2014et al. et al
recombination resulted in a ubiquitous disruption of the CrT gene. In particular, the reduction of
serum Cr level may be explained by defective gut absorption from the diet (Garcia-Miranda ,et al.
; Skelton , 2011). The only body fluid in which Cr levels resulted to be increased is urine;2009 et al.
it is likely that the lack of a functional transporter impairs the creatine salvage normally operated by
the kidney ( ). Consistently, we found an elevated creatine/creatininevan de Kamp , 2014et al.
(Cr/Crn) ratio in the urine of mutant mice, probably due to a combination of reduced renal
reabsorption of creatine and decreased creatinine excretion.” Since we found a strong reduction of
creatine concentration, we don’t think that blood contamination could be responsible for higher
brain Cr levels in these mice. Finally, we provided the information on GAA content in organs and
body fluids, adding a Table 2 to the manuscript. 
 No competing interests were disclosed.Competing Interests:
−/y
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 05 November 2014Referee Report
doi:10.5256/f1000research.5732.r6560
 Luis M. Valor
Instituto de Neurociencias de Alicante (Universidad Miguel Hernández - Consejo Superior de
Investigaciones Científicas), Alicante, Spain
In “A novel mouse of creatine transporter deficiency” the authors describe the phenotype of a new
knockout mouse for  gene which is associated with a depletion in the levels of creatine in diverseSlc6a8
organs. This phenotype is reminiscent of the CCDS1 symptomatology, therefore the main output of the
present report is an increase in the number of available murine models for this disorder as claimed in the
article.
 
The paper is well written and the work is well presented, with no major concerns regarding the data as
shown. Nonetheless, I miss a more complete behavioural analysis. In some cases this is not crucial
because assessment of particular tasks is expected to support current findings (absence of anxiety in the
open field or impaired spatial working memory in the Y-maze) although with the strength of using more
dedicated paradigms (elevated plus maze or T-maze based on a rewarding system, respectively).
However, it is more relevant in the case of motor and neuromuscular deficits to enhance the conclusions
obtained from spontaneous activity measurements, and other approaches (accelerating rotarod, grip
strength, vertical pole, etc. to put some examples) may be more informative.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response 15 Jan 2015
, CNR Institute of Neuroscience, Italy, ItalyLaura Baroncelli
We agree that a more detailed behavioral analysis (in particular dedicated to the understanding of
motor and neuromuscolar deficits) would be informative for the characterization of CCDS1 murine
models. We plan to do this in our next paper. 
 No competing interests were disclosed.Competing Interests:
 02 October 2014Referee Report
doi:10.5256/f1000research.5732.r6247
 Benedetto Sacchetti
Department of Neuroscience, University of Turin, Turin, Italy
In the present paper the authors describe a new murine model of CCDS1 obtained by ubiquitous deletion
of 5-7 exons in the gene. The experiments in general are well controlled and the results could beSlc6a8 
of interest for a general audience. However, I think there are two related points that should be added or
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of interest for a general audience. However, I think there are two related points that should be added or
clarified before the paper can be considered for publication.
 
The authors reported that Cr depletion altered spontaneous locomotor behavior (Fig 7) and reduced
muscle levels. How can this data fit with the normal behavior (namely, the motion speed and the total
distance moved) displayed by mutant animals in the open field test?
 
On the other hands, can the authors exclude that the aforementioned reduced motor activity may have
interfere with learning and memory trials? The authors should at least discuss this possibility.
 
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Author Response 06 Nov 2014
, CNR Institute of Neuroscience, Italy, ItalyLaura Baroncelli
We agree that the difference between the altered spontaneous locomotor behavior of
mutant animals in the home cage and the normal exploratory disposition in the open field
arena can be a little bit surprising. However, we feel that the lack of a genotype effect for the
latter measure may be due to the aversive nature of the open field arena, which may affect
the explorative behavior of both wild-type and mutant mice, thus masking the difference in
motor activity between the two groups.
 
We think that our data allow to exclude the possibility that an impaired motor activity can
interfere with the presented results of learning and memory test. We found that, during the
ORT sample phase, the total exploration time of objects was equal for mutant and control
mice (Figure 4a), and animals of both groups equally explored the Y maze in terms of both
the number of entries in the single arms of the maze and the total number of arm entries
(Figure 5b). These results strongly suggest that animals’ level of activity does not affect their
cognitive performance. As for the Morris water maze during the training phase we analyzed
the path length covered to locate the submerged platform just to avoid the confounding
effects of the reduced swimming speed observed in mutant mice that should not affect
instead the performance in the probe trial.
 No competing interests were disclosed.Competing Interests:
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